Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine

Biologicals

Volumn 26, Issue 2, 1998, Pages 145-153

  Auerbach, Barry S ^a,b   Lake, Alan M ^b   Wilson, Modena E ^b   Willingham, Field F ^a   Shematek, Jon ^c   Moulton, Lawrence ^a   Deforest, Adamadia ^d   Halsey, Neal A ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Patuxent Medical Group   (United States)

^d TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGGLUTININ; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TOXOID; HEMAGGLUTININ; PERTUSSIS TOXIN; PERTUSSIS VACCINE; TETANUS TOXOID;

ANOREXIA; ARTICLE; COMPARATIVE STUDY; CRYING; ERYTHEMA; FEVER; HUMAN; IMMUNOGENICITY; INFANT; IRRITABILITY; NORMAL HUMAN; PAIN; PRIORITY JOURNAL; SEROLOGY; SOMNOLENCE;

EID: 0031726018     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1006/biol.1998.9999     Document Type: Article

References (44)

1. Greco D, Salmaso S, Mastrantonio P et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N Engl J Med 1996; 334: 341-348.
2. Gustafsson L, Hallander HO, Olin P et al. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine [published erratum appears in N Engl J Med 1996 May 2; 334(18): 1207]. N Engl J Med 1996; 334: 349-355.
3. Trollfors B, Taranger J, Lagergard T et al. A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med 1995; 333: 1045-1050.
4. International Symposum on Pertussis Vaccine Trials, Rome, 30 October-1 November 1995: trial synopses. Rome: Istituto Superiore di Sanita, 1995; (Abstract).
5. Schmitt HJ, von Konig CH, Neiss A et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996; 275: 37-41.
6. Edwards KM, Decker MD. Acellular pertussis vaccines for infants (editorial; comment). N Engl J Med 1996; 334: 391-392.
7. Halsey NA, Peter G. New developments with pertussis vaccines. Pediatrics 1995; 96: 970-971.
8. Fine PE, Clarkson JA. Reflections on the efficacy of pertussis vaccines. Rev Infect Dis 1987; 9: 866-883.
9. Decker MD, Edwards KM, Steinhoff MC et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 1995; 96: 557-566.
10. Deloria MA, Blackwelder WC, Decker MD et al. Association of reactions after consecutive acellular or whole-cell pertussis vaccine immunizations. Pediatrics 1995; 96: 592-594.
11. Baraff LJ, Cody CL, Cherry JD. DTP-associated reactions: an analysis by injection site, manufacturer, prior reactions, and dose. Pediatrics 1984; 73: 31-36.
12. Cody CL, Baraff LJ, Cherry JD et al. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics 1981; 68: 650-660.
13. Barkin RM, Pichichero ME. Diphtheria-pertussis-tetanus vaccine: reactogenicity of commercial products. Pediatrics 1979; 63: 256-260.
14. Steinhoff MC, Reed GF, Decker MD et al. A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines. Pediatrics 1995; 96: 567-570.
15. Noble GR, Bernier RH, Esber EC et al. Acellular and whole-cell pertussis vaccines in Japan. Report of a visit by US scientists. JAMA 1987; 257: 1351-1356.
16. Mortimer EA, Jr., Kimura M, Cherry JD et al. Protective efficacy of the Takeda acellular pertussis vaccine combined with diphtheria and tetanus toxoids following household exposure of Japanese children. Am J Dis Children 1990; 144: 899-904.
17. Aoyama T, Murase Y, Kato T et al. Efficacy of an acellular pertussis vaccine in Japan. J Pediatr 1985; 107: 180-183.
18. Isomura S, Suzuki S, Sato Y. Clinical efficacy of the Japanese acellular pertussis vaccine after intrafamiliar exposure to pertussis patients. Dev Biol Stand 1985; 61: 531-537.
19. Aoyama T, Murase Y, Gonda T et al. Type-specific efficacy of acellular pertussis vaccine. Am J Dis Children 1988; 142: 40-42.
20. Aoyama T, Murase Y, Kato M et al. Efficacy and immunogenicity of acellular pertussis vaccine by manufacturer and patient age. Am J Dis Children 1989; 143: 655-659.
21. Morgan CM, Blumberg DA, Cherry JD et al. Comparison of acellular and whole-cell pertussis-component DTP vaccines. A multicenter double-blind study in 4- to 6-year-old children. Am J Dis Children 1990; 144: 41-45.
22. Edwards KM, Bradley RB, Decker MD et al. Evaluation of a new highly purified pertussis vaccine in infants and children. J Infect Dis 1989; 160: 832-837.
23. Pichichero ME, Badgett JT, Rodgers GC, Jr. et al. Acellular pertussis vaccine: immunogenicity and safety of an acellular pertussis vs. a whole cell pertussis vaccine combined with diphtheria and tetanus toxoids as a booster in 18- to 24-month old children. Pediatr Infect Dis J 1987; 6: 352-363.
24. Anderson EL, Belshe RB, Bartram J et al. Clinical and serologic responses to acellular pertussis vaccine in infants and young children. Am J Dis Children 1987; 141: 949-953.
25. Edwards KM, Lawrence E, Wright PF. Diphtheria, tetanus, and pertussis vaccine. A comparison of the immune response and adverse reactions to conventional and acellular pertussis components. Am J Dis Children 1986; 140: 867-871.
26. Lewis K, Cherry JD, Holroyd HJ et al. A double-blind study comparing an acellular pertussis-component DTP vaccine with a whole-cell pertussis-component DTP vaccine in 18-month-old children. Am J Dis Children 1986; 140: 872-876.
27. Edwards KM, Meade BD, Decker MD et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 1995; 96: 548-557.
28. Anderson EL, Belshe RB, Bartram J. Differences in reactogenicity and antigenicity of acellular and standard pertussis vaccines combined with diphtheria and tetanus in infants. J Infect Dis 1988; 157: 731-737.
29. Blennow M, Granstrom M, Jaatmaa E et al., Primary immunization of infants with an acellular pertussis vaccine in a double-blind randomized clinical trial. Pediatrics 1988; 82: 293-299.
30. Ad Hoc Group for the Study of Pertussis Vaccines. Placebo-controlled trial of two acellular pertussis vaccines in Sweden - protective efficacy and adverse events [published erratum appears in Lancet 1988 May 28; i(8596): 1238]. Lancet 1988; i: 955-960.
31. Auerbach BS, Wilson ME, Lake AM et al. Dose-response to acellular pertussis vaccine and comparison with whole cell pertussis vaccine at 15-24 months and 4-6 years of age. Acellular Pertussis Vaccine Study Team. Vaccine 1992; 10: 14-20.
32. Meinert C. Clinical Trials: Design, Conduct and Analysis. New York, New York: Oxford University Press, 1986.
33. Manclark CR, Meade BD, Burstyn D. Serological response to Bordetella pertussis. In: Rose N, Frienman H, Fahey JL (eds) Manual of Clinical Laboratory Immunology. Washington, DC: American Society for Microbiology, 1986; pp. 388-394.
34. Gillenius P, Jaatmaa E, Askelof P et al., The standardization of an assay for pertussis toxin and antitoxin in microplate culture of Chinese hamster ovary cells. J Biological Stand 1985; 13: 61-66.
35. Miyamura K, Nishio S, Ito A et al. Micro cell culture method for determination of diphtheria toxin and antitoxin titers using VERO cells. I. Studies on factors affecting the toxin and antitoxin titration. J Biological Stand 1974; 2: 189-201.
36. Hardegree MC, Barile MF, Pittman M et al. Immunization against neonatal tetanus in New Guinea. 4. Comparison of tetanus antitoxin titers obtained by haemagglutination and toxin neutralization in mice. Bull WHO 1970; 43: 461-468.
37. Ipsen J. Circulating antitoxin at the onset of diphtheria in 425 patients. J Immunol 1954; 54: 325-347.
38. Ipsen J. Immunization of adults against diphtheria and tetanus. N Engl J Med 1954; 251: 459-466.
39. McComb JA, Dwyer RC. Passive active immunization with tetanus immune globulin (human). N Engl J Med 1963; 268: 857-862.
40. McComb JA. The prophylactic dose of homologous tetanus antitoxin. N Engl J Med 1964; 270: 175-178.
41. MacLennan R, Schofield FD, Pittman M et al. Immunization against neonatal tetanus in New Guinea. Antitoxin response of pregnant women to adjuvant and plain toxoids. Bull WHO 1965; 32: 683-697.
42. Edwards KM, Decker MD, Halsey NA et al. Differences in antibody response to whole-cell pertussis vaccines. Pediatrics 1991; 88: 1019-1023.
43. International Symposium on Pertussis Vaccine Trials, Rome; 30 October-1 November 1995. In: Trial Synopses. Rome: Institute Superiore di Sanitá; 1995.
44. American Academy of Pediatrics Committee on Infectious Diseases. Acellular Pertussis Vaccine: Recommendations for Use as the Initial Series in Infants and Children. Pediatrics 1997; 99(2): 282-288.